Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
SWOG Cancer Research Network
Cancer Research UK
ADC Therapeutics S.A.
Children's Oncology Group
Fred Hutchinson Cancer Center
Dartmouth-Hitchcock Medical Center
Massachusetts General Hospital